TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01752127

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention using drug eluting stent
Description: 1. Intracoronary stenting~1. The procedure could be conducted via brachial, radial or femoral approaches.~2. There are no restrictions regarding lesion's length or diameter. For long lesions, overlapping of several stents would be allowed but only allocated type of stents should be used.~3. When several lesions are included in the study of a patient, each lesion may be allocated in different groups. Only if deployment of the allocated stent is not possible, crossing to other stent would be allowed.~4. Direct stenting or bifurcation stenting is allowed.~5. Predilation before stenting, IVUS examination, and administration of glycoprotein IIb/IIIa inhibitor would be determined by investigator.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention using drug eluting stent
Description: 1. Intracoronary stenting~1. The procedure could be conducted via brachial, radial or femoral approaches.~2. There are no restrictions regarding lesion's length or diameter. For long lesions, overlapping of several stents would be allowed but only allocated type of stents should be used.~3. When several lesions are included in the study of a patient, each lesion may be allocated in different groups. Only if deployment of the allocated stent is not possible, crossing to other stent would be allowed.~4. Direct stenting or bifurcation stenting is allowed.~5. Predilation before stenting, IVUS examination, and administration of glycoprotein IIb/IIIa inhibitor would be determined by investigator.
Study: NCT03628677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
Study: NCT05117437

Intervention type: OTHER
Intervention: Physiological test
Description: This test was conducted to determine the endurance levels of the participants.

Intervention type: OTHER
Intervention: Physiological test
Description: This test was conducted to determine the endurance levels of the participants.

Intervention type: OTHER
Intervention: Physical test
Description: Height, weight, and BMI were determined

Intervention type: OTHER
Intervention: Physical test
Description: Height, weight, and BMI were determined

Intervention type: OTHER
Intervention: Biochemical tests
Description: BMP9, CTX1, COMP, oxLDL protein levels, ALP, GGT, TAS, TOS, OSI, NO, calcium, T-C, LDL-C, Triglyceride, HDL-C, glucose, CRP, AST, ALT, erythrocyte, mean erythrocyte volume (MCV), hematocrit, leukocyte, thrombocyte levels were determined from blood samples.

Intervention type: OTHER
Intervention: Biochemical tests
Description: BMP9, CTX1, COMP, oxLDL protein levels, ALP, GGT, TAS, TOS, OSI, NO, calcium, T-C, LDL-C, Triglyceride, HDL-C, glucose, CRP, AST, ALT, erythrocyte, mean erythrocyte volume (MCV), hematocrit, leukocyte, thrombocyte levels were determined from blood samples.
Study: NCT00160693

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: 400 mg of Certolizumab Pegol subcutaneously every 4 Weeks
Study: NCT05217147

Intervention type: OTHER
Intervention: Obtaining blood samples
Description: Blood samples were obtained at time of diagnosis and will be analyzed for the levels of biomarker candidate molecules.
Study: NCT01151176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Insulin
Description: 1,8U Regular insulin/h from 180mg/dL of blood glucose increasing each hour according to capillary blood glucose. Between 100-150mg/dL keep infusion and bellow 100mg/dL stop infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Regular Insulin
Description: Regular Insulin SC according to Blood Glucose(mg/dL) and Insulin Sensitive with usual dose describe and less 2U for sensitive and plus 2U for insulin resistant:~Blood Glucose \>141-180=4U ;181-220=6U; 221-260=8U; 261-300=10U;301-350=12U; 351-400=14U; \> 400=16U
Study: NCT04055025

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Four-hour liquid solid meal tests and a subsequent ad libitum meal during saline infusion.

Intervention type: OTHER
Group type: OTHER
Intervention: Ghrelin
Description: Four-hour liquid solid meal tests and a subsequent ad libitum meal during acyl-ghrelin infusion.
Study: NCT01121952

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chiropractic (HVLA) manipulation
Description: Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation to the talo-crural joint, once a week during a three week period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic (HVLA) manipulation
Description: Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation to the talo-crural joint, once a week during a three week period
Study: NCT01553760

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification using an ACM as the sole fluid source
Description: A Tri-MICS system will be used with a sleeveless Kelman 20G tip through a 1.1mm CCI. A specialized 19G anterior chamber maintainer, with thin walls and a large internal diameter of 0.9mm will be inserted through a 1.1mm CCI.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Phaco
Description: a conventional Phaco with sleeved Kelman 20G tip, through a 2.4mm CCI
Study: NCT03190967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: T-DM1 3.6 mg/kg intravenous (IV) every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T-DM1
Description: T-DM1 3.6 mg/kg intravenous (IV) every 21 days
Study: NCT03688126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Guided Lifestyle Intervention
Description: Lifestyle intervention that involves providing participants with education, support, and tangible tools to assist them in developing and carrying out healthier lifestyle practices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Lifestyle Intervention
Description: Lifestyle intervention that involves a structured program of diet, physical and cognitive exercise, and management of cardiometabolic risks.
Study: NCT04184895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP2390
Description: Intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP2390
Description: Intradermal

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal; normal saline solution

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal; normal saline solution
Study: NCT03190967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: T-DM1 3.6 mg/kg intravenous (IV) every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: Phase I: TMZ 30, 40 or 50 mg/m\^2 daily Phase II: TMZ at recommended phase 2 dose (RP2D) estimated in Phase I dose escalation part of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: Phase I: TMZ 30, 40 or 50 mg/m\^2 daily Phase II: TMZ at recommended phase 2 dose (RP2D) estimated in Phase I dose escalation part of the study.
Study: NCT01517906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identity Intervention Program
Description: Cognitive behavioral strategies will be used by trained nurse-therapists to facilitate the participant's: a) identification of a small collection of personally meaningful and feasible desired possible selves, b) prioritization of the desired possible selves as short and long-term goals, c) identification, elaboration, implementation and evaluation of cognitive and behavioral strategies to achieve the desired possible self selected as the goal, and d) identification of internal and external barriers that interfere with achieving the possible self goal and utilization of active problem solving strategies to overcome the barriers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy for the Eating Disorders
Description: SPI is a 20-week program with a one-hour individual psychotherapy session scheduled each week. The SPI is organized in three stages: 1) Stage 1 (Sessions 1-8) including assessment of the current and past ED history, collection of personal and family history, and identification of problems contributing to the ED; 2) Stage 2 (Sessions 9-16) aims include exploration of underlying emotional problems, increased self-disclosure and expression of feelings, and fostering independence; and 3) Stage 3 (Sessions 17-20) includes continued exploration of underlying problems and implications for future behaviors and termination.
Study: NCT04313504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib \& Dostarlimab combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Niraparib \& Dostarlimab combination
Study: NCT02527902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter
Description: measure of ANS in IgAN patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter
Description: measure of ANS in IgAN patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter
Description: measure of ANS in IgAN patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter
Description: measure of ANS in IgAN patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter
Description: measure of ANS in IgAN patients
Study: NCT03156413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P nasal mask
Description: Investigative Nasal Mask to be used for OSA therapy
Study: NCT03103776

Intervention type: OTHER
Group type: OTHER
Intervention: Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto
Description: Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto

Intervention type: OTHER
Group type: OTHER
Intervention: Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto
Description: Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto
Study: NCT00638690

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four tablets once daily until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Four 250-mg tablets once daily until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone/prednisolone
Description: 5 mg twice daily until disease progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone/prednisolone
Description: 5 mg twice daily until disease progression
Study: NCT00605358

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Open Door intervention
Description: Open Door intervention subjects will:~1. receive an evaluation~2. receive a referral to a local mental health provider~3. identify barriers, set goals and problem-solve to achieve a mental health evaluation using available resources.
Study: NCT03625804

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PNS+AO+Training
Description: Electrical stimulation was applied to the radial and ulnar nerve (PNS) of the paretic arm for 60 minutes. During the last 30 minutes of PNS, action observation (AO) was introduced in which subjects were required to watch a series of video clips. After one hour's PNS+AO, the subjects then proceeded to a 30-minute period of motor training of paretic hand.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PNS+AOsham+Training
Description: PNS was given as described before. During the last 30 minutes of the PNS, subjects were shown different photos illustrating a letter, a number or a hand as AOsham. The protocol of motor training was the same as described before.

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: PNSsham+AOsham+Training
Description: The 1-hour PNSsham was conducted with the electrical stimulation unit turned on but without current output. The protocols for AOsham and motor training were the same as those described before.
Study: NCT00002968

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: edrecolomab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02044315

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ICD programming

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICD programming
Study: NCT00115544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stanate
Description: Intramuscular injection of stannsoporfin at 0.75 or 1.5mg/kg for treatment of severe hyperbilirubinemia to prevent exchange transfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stanate
Description: Intramuscular injection of stannsoporfin at 0.75 or 1.5mg/kg for treatment of severe hyperbilirubinemia to prevent exchange transfusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stanate
Description: Intramuscular injection of stannsoporfin at 0.75 or 1.5mg/kg for treatment of severe hyperbilirubinemia to prevent exchange transfusion
Study: NCT02128204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lidocaine contained hyaluronate facial dermal filler
Description: HYADERMIS LA Facial Dermal Implant contains 20 mg/ml hyaluronate and 0.3 % lidocaine.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronate facial dermal filler
Description: Hya-Dermis Facial Dermal Implant contains 20 mg/ml hyaluronate.
Study: NCT01498497

Intervention type: DRUG
Intervention: EUR-1100

Intervention type: DRUG
Intervention: Placebo
Study: NCT02480868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARTEBONE
Description: 4,3 g Bone Void Filler
Study: NCT00317707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-3 Polyunsaturated Fatty Acids
Description: Each subject assigned to active treatment group will receive 1g/day capsule of n-3 PUFA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Olive oil
Description: Each subject assigned to the control group will receive 1 g/day capsule of olive oil.
Study: NCT00896480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic GSK2132231A
Description: Administration by intramuscular injection
Study: NCT01648660

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein/ Zeaxanthin + Omega- 3- Fatty Acids
Description: capsule with Lutein, Zeaxanthin, Omega-3-FA for two years

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein/ Zeaxanthin + Omega- 3- Fatty Acids
Description: capsule with Lutein, Zeaxanthin, Omega-3-FA for two years

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein/ Zeaxanthin + Omega- 3- Fatty Acids
Description: capsule with Lutein, Zeaxanthin, Omega-3-FA for two years
Study: NCT03093389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512
Description: The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 100 mg and 150 mg. Products were administered orally, with approximately 240 mL of water in case of Doses 1 and 13, and at least 150 mL of water in case of Doses 2 to 12. First dose (Dose 1) and last dose (Dose 13) were administered in fasting of at least 8 hours and subject remained fasted until to 2.5 h post-dose. Meals were not served within 1 hour prior and 1 hour after investigational product administration in Doses 2 to 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512
Description: The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 100 mg and 150 mg. Products were administered orally, with approximately 240 mL of water in case of Doses 1 and 13, and at least 150 mL of water in case of Doses 2 to 12. First dose (Dose 1) and last dose (Dose 13) were administered in fasting of at least 8 hours and subject remained fasted until to 2.5 h post-dose. Meals were not served within 1 hour prior and 1 hour after investigational product administration in Doses 2 to 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512
Description: The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 100 mg and 150 mg. Products were administered orally, with approximately 240 mL of water in case of Doses 1 and 13, and at least 150 mL of water in case of Doses 2 to 12. First dose (Dose 1) and last dose (Dose 13) were administered in fasting of at least 8 hours and subject remained fasted until to 2.5 h post-dose. Meals were not served within 1 hour prior and 1 hour after investigational product administration in Doses 2 to 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512
Description: The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 100 mg and 150 mg. Products were administered orally, with approximately 240 mL of water in case of Doses 1 and 13, and at least 150 mL of water in case of Doses 2 to 12. First dose (Dose 1) and last dose (Dose 13) were administered in fasting of at least 8 hours and subject remained fasted until to 2.5 h post-dose. Meals were not served within 1 hour prior and 1 hour after investigational product administration in Doses 2 to 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules
Study: NCT01410786

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Instrumentation
Description: Standard Oxford surgical instruments

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Signature Custom Guides
Description: Signature Custom Guides used with Instruments in surgical technique
Study: NCT02940197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MediterrAsian diet
Description: no other description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MediterrAsian diet
Description: no other description
Study: NCT02762045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-gag
Description: Ad5-gag is used as vaccine in all arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-gag
Description: Ad5-gag is used as vaccine in all arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-gag
Description: Ad5-gag is used as vaccine in all arms.
Study: NCT04020965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water Treatment
Description: Hardware: Chlorine dispensers provided for free at communal water sources, available to households in intervention arm who were and who were not enrolled in the WASH Benefits Kenya study.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on the treatment of drinking water for all children living in the household. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits. After the completion of the WASH Benefits Kenya study, the NGO Evidence Action conducted educational campaigns to promote the use of dispensers.
Study: NCT02762045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Preservation Solution is used as control in all arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Preservation Solution is used as control in all arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Preservation Solution is used as control in all arms.
Study: NCT00023205

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 11th grade reading level arthritis materials

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive in-person arthritis education
Study: NCT00554853

Intervention type: DRUG
Group type: OTHER
Intervention: pioglitazone
Description: daily dose, 30 mg daily for 2 weeks followed by 45 mg daily until completing 3 months unless higher dose not tolerated in which case patient remained at 30 mg daily

Intervention type: DRUG
Group type: OTHER
Intervention: pioglitazone
Description: daily dose, 30 mg daily for 2 weeks followed by 45 mg daily until completing 3 months unless higher dose not tolerated in which case patient remained at 30 mg daily

Intervention type: DRUG
Group type: OTHER
Intervention: Sublingual nitroglycerine
Description: Used during nitroglycerin-mediated dilatation vascular function measures in both arms of the study if patient's blood pressure permitted. One single tablet was used per vascular test performed.

Intervention type: DRUG
Group type: OTHER
Intervention: Sublingual nitroglycerine
Description: Used during nitroglycerin-mediated dilatation vascular function measures in both arms of the study if patient's blood pressure permitted. One single tablet was used per vascular test performed.
Study: NCT02128919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial Direct Current Stimulation
Study: NCT03496922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Tobacco Marketplace
Description: See arm group description.
Study: NCT02128919

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Transcranial Direct Current Stimulation
Study: NCT04212403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: The control group receives AMP.
Study: NCT04104204

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intrathecal morphine
Description: 0.5% Iso/Hyperbaric bupivacaine 2-3 ml add morphine 0.1 mg for spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound guided supra-inguinal fascia iliaca block
Description: Ultrasound guided supra-inguinal fascia iliaca block with 0.25% bupivacaine 40 ml and 0.5% Iso/Hyperbaric bupivacaine 2-3 ml without spinal morphine for spinal anesthesia